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  ABSTRACT 
 
OBJECTIVE: Myeloproliferative Neoplasms are rare, poorly understood 
diseases in children, and the outcomes, causative lesions, and management 
strategies for children with these diseases are not clearly defined.  The 
purpose of this study was to evaluate clinical findings and management 
practices in children with MPN, and identify alternative genetic lesions that 
could contribute to disease pathogenesis in these patients.   
METHODS: Patients were identified as eligible if they were diagnosed with a 
BCR-ABL negative classical MPN.  They were enrolled and provided our team 
with clinical information, including age of presentation, bone marrow pathology 
results, and treatments utilized.  Blood and buccal samples were collected 
(and bone marrow if available.)  Monocytes and granulocytes were separated 
from blood and marrow samples, and DNA was extracted from all three types 
of tissue (tumor samples = granulocytes and monocytes; normal tissue = 
buccal cells.)  Next-generation sequencing was performed on these samples 
for a pre-determined panel of genes known to be relevant in hematologic 
malignancies and myeloproliferative neoplasms. 
RESULTS: Ten patients were enrolled on study but two were removed when 
their bone marrow biopsies ruled out a myeloproliferative neoplasm.  Of the 
eight children eligible to remain in the study, known causative mutations were 
identified on clinical testing in three of them to date.  Next-generation 
sequencing did not show alternative mutations in JAK2, MPL, or CALR.  No 
children have yet had major thrombotic or hemorrhagic complications.  Six 
children received hydroxyurea for their symptoms.  None of the 8 subjects 
have developed leukemia at this time. 
CONCLUSIONS: Children with myeloproliferative neoplasms may have lower 
rates of severe complications and known genetic mutations than adults with 
similar diseases.  More study is needed of this rare population of patients to 
better quantify clinical outcomes, genetic lesions, and allow for development of 
appropriate treatment algorithms.  
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INTRODUCTION 
 
 Myeloproliferative Neoplasms (MPN) are defined as clonal disorders 
leading to overproduction of hematopoietic cells1.  Chronic Myelogenous 
Leukemia (CML), known to be associated with the BCR-ABL translocation 
(also called the Philadelphia Chromosome – Ph) is one of the best recognized 
of the MPN.  Amongst the Ph (-) MPN, the three classic disorders are 
Essential Thrombocytosis (ET), Polycythemia Vera (PV) and Primary 
Myelofibrosis (PMF).  There are a number of different criteria used for the 
diagnosis of these diseases, including those put out by the WHO and the 
Polycythemia Vera Study Group.  They include genetic findings (such as 
absence of the BCR-ABL translocation), clinical and lab features, and specific 
findings in bone marrow (such as comments on cellularity, fibrosis, and 
appearance of precursor cells), and the exclusion of reactive causes2,3. 
 The clinical course of these diseases is well studied in adult patients, 
and symptoms can include headache, pruritus, erythromelalgia, and 
splenomegaly4.  Dangerous complications include severe bleeding, thrombotic 
events, and transformation to Myelodysplastic Syndrome (MDS) or Acute 
Myelogenous Leukemia5,6 (AML).  The genetic landscape of these diseases is 
also well understood.  In 2005, the Janus Kinase (JAK) 2-gene mutation 
JAK2V617F was found to be a key driving force in MPN7,8,9.  We know now 
that a large majority of adults with PV harbor this mutation, as well as ~ 50% 
of patients with ET or PMF.  It was then discovered that the thrombopoietin 
receptor gene MPL also played a role as a causative mutation, with ~3-5% of 
patients with ET and 5-10% of patients with MF having mutations in the MPL 
gene, the most common of which is the MPLW5151K/L mutation10,11.  More 
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recent studies have identified mutations in CALR in a significant number of 
JAK2 and MPL-negative patients12,13.  Additional genes have been shown to 
play a role in pathogenesis as well, including TET2, ASXL1, and 
EZH214,15,16. 
 There are non-sporadic forms of MPN as well.  Familial forms of MPN 
have similar clinical features as the classical sporadic MPN, and members of 
the affected family can have the same or different MPNs.  These generally 
involve mutations in JAK, MPL or TERT2 genes.  Hereditary forms of MPN 
(hereditary thrombocytosis or erythrocytosis) are polyclonal and have milder 
clinical phenotypes with low likelihood of transformation.  Erythrocytosis is 
typically due to mutations in EPOR, VHL, HIF1α and HIF2α and 
thrombocytosis is generally due to mutations in the TPO or MPL genes17. 
 Management of MPN in adults is based on clinical findings and risk 
stratifications.  Higher risk features for various MPN include older age, prior 
history of thrombosis, severity of anemia, presence of constitutional 
symptoms, and high white blood cell count, depending on the type of MPN.  
Treatments may involve phlebotomy (for PV), aspirin, or cytoreductive therapy 
for higher risk patients, such as Hydroxyurea, Anagrelide (for ET), or 
Interferon.  Targeted therapies with JAK inhibition have recently been 
approved for PMF and PV18.    
 While there have been significant advances in our understanding of 
adult MPN, there is a paucity of knowledge regarding pediatric MPN.  The 
limited available literature suggests that children with MPN do not harbor the 
known pathogenic mutations at the same frequency as adults19,20.  While 
current literature suggests that complication rates are lower in children, the 
existing data is limited.  No accepted treatment guidelines exist for children 
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with MPN, and recommendations on management of these disorders in 
children are limited2,21,22.  The clear lack of expertise surrounding the causes 
and management of MPN in children is the driving force behind this research. 
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  MATERIALS AND METHODS 
 
Setting 
 This study was conducted at the New York Presbyterian/Weill Cornell 
Medical Center, in both the pediatric inpatient unit and outpatient pediatric 
hematology/oncology clinic.  The Institutional Review Board of the Weill 
Cornell Medical College approved this study.  Participants were either primary 
hematology patients of the center, patients who were interested in participating 
in pediatric MPN research, or patients primarily based at other centers that 
were being cared for by our pediatric hematology service.  Clinical information 
was obtained in the inpatient and outpatient units.  Processing of de-identified 
samples for DNA extraction and genetic sequencing took place in the Levine 
lab and in the Integrated Genomics Operation core facility at the Memorial 
Sloan-Kettering Cancer Center. 
 
Participants 
 This study was a prospective observational study of pediatric MPN 
patients (as defined by the WHO 2008 Diagnostic Criteria).  Anyone aged 0-21 
years who was diagnosed with a Philadelphia-chromosome negative MPN 
prior to his or her 18th birthday is eligible.  Consent was provided for minor 
subjects by their parent or legal guardian.  Children aged 7 years to 17 years 
also provided assent for the study.  Any subject enrolled at the time of work-up 
who was then determined not to have an MPN was removed from the study 
and samples were discarded.  Upon study enrollment, participants are given a 
subject number to ensure data is de-identified. 
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Clinical Information 
 Participants’ medical records were reviewed to ensure they were 
diagnosed with an MPN or were being evaluated for one after consent was 
signed.  All available relevant information regarding the diagnosis, including 
past medical history, history of presenting illness, complete blood counts, bone 
marrow examinations, and supporting laboratory studies were documented.  
The REDCap database system will be utilized as the primary database tool to 
store pertinent clinical information. 
 
Sample Collection 
 At the time of scheduled clinical blood draws, 1-3 additional EDTA 
tubes of peripheral blood was collected for future isolation of white blood cells, 
depending on the age and size of the patient.  If a bone marrow aspiration was 
being performed as part of routine clinical care, 1-2 additional tubes of bone 
marrow aspirate was collected.  To obtain germline sample, oral buccal 
mucosal cells were collected by having the subject rinse and spit with 10 
milliliters of original Scope™ mouthwash. 
 
DNA Extraction from Blood and Buccal Samples 
 Utilizing a Ficoll-Paque™ density gradient separation technique (per 
manufacturer’s recommended protocol), mononuclear cells and granulocytes 
were separated and extracted from peripheral blood and bone marrow 
samples.  DNA was then extracted from these cells utilizing a Qiagen™ DNA 
extraction kit according to the manufacturer’s recommended protocol.  A 
Qiagen™ DNA extraction kit was also utilized to extract DNA from buccal cells 
in mouthwash.  
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Sequencing of Potential Genes of Significance  
 A multi-gene MPN/Leukemia panel (close to 400 genes) was designed 
incorporating known genes of relevance or interest in MPN, and lymphoid and 
myeloid malignancies.  DNA from subject samples were plated and submitted 
for next-generation sequencing to evaluate for mutations in the genes of 
interest.  Nimblegen capture was utilized to obtain libraries of sequence 
correlating to the protein-coding exons of the included genes.  Captured DNA 
was then sequenced using an Illumina HiSeq 2500.  The Burrows-Wheeler 
Aligner was used to align sequence reads to the reference genome23 and 
post-processing occurred utilizing the Genome Analysis Toolkit24.  Paired 
analysis was done if adequate buccal sample was available.  Copy number 
and sequence variants were identified and reviewed. 
 
Cell Lines 
293T cells were grown in Dulbecco’s modified Eagle’s medium with 
10% FBS. 293T cells were transiently co-transfected and retroviral 
supernatant was produced using Fugene (Roche, Nutley, NJ, USA) according 
to manufacturer’s procedure. Ba/F3 cells (grown in RPMI-1640 + 10% fetal 
bovine serum (FBS) + 1U/ml IL-3) were transduced with MSCV-hJAK1V658F-
GFP.  Ba/F3 hJAK1V658F GFP cells were selected out by withdrawl of IL-3 
from the growth media. 
 
In vitro inhibitor assays and Western blot analysis 
Viable cells were plated at 10,000 cells/well in 96 well tissue culture 
treated plates in 200uL media with increasing concentrations of INCB18424 
inhibitor or PU-H71 inhibitor in triplicate. 48 hour inhibitor assays were 
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assessed using the Cell viability luminescence assay (CellTiter-Glo®, 
Promega, Cat. No. G7571). Analysis based on normalization to cells treated 
with DMSO, media with DMSO, and media only.  The effective dose for 50% 
death was determined using Graph Pad Prism 5.0 software. Western blot 
analysis of the cell signaling pathway were evaluated at steady state, and then 
determined at either 4 hour or 16h time points with inhibitor treatment. Cells 
were collected in lysis buffer containing Protease Arrest (Geno Technology), 
Phosphatase Cocktail II  (EMD Chemicals), PMSF, and PAO, protein 
normalized using the Bio-Rad Bradford protein estimation, and separated 
using 4-12% Bis-Tris electrophoresis gels (Invitrogen). Nitrocellulose 
membranes were blocked in TBS-T with 5% milk and incubated with 
appropriate dilutions of primary and secondary antibody
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RESULTS 
 
Subject Demographics 
Ten children were enrolled during the study period based on a current 
or working diagnosis.  On evaluation, two patients were identified as not 
having a classical MPN and are not included in the analysis.  Of the remaining 
eight children, all had a diagnosis of MPN.  Their ages ranged from 8-21 years 
old.  Three males and five females enrolled (Table 1.)  Three children were 
followed at our center, one was followed at a local center, and four received 
their primary hematologic care at distant medical centers. 
 
      Table 1 – Summary of Enrolled Subjects 
Subject # Diagnosis Age at Diagnosis (yrs) Gender 
1 ET 0.5 M 
2 ET 6 M 
3 ET 12 F 
4 ET 5 F 
5 ET 7 F 
6 PMF 13 M 
7 ET 11 F 
8 ET 19 F 
        yrs = years 
 
Clinical Analysis 
Diagnosis 
Seven subjects had a diagnosis of ET and one patient had a diagnosis 
of ET that was later corrected to a diagnosis of PMF.  Seven of the eight 
subjects had bone marrow evaluations done as part of their diagnostic work-
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up, and only one (subject #8) did not have a bone marrow done (her physician 
made her diagnosis based on clinical and genetic findings.)  Therefore, except 
for subject #8, all subjects were diagnosed in accordance with WHO criteria.  
No children with PV were enrolled.  Age at diagnosis ranged from 6 months of 
age to 19 years old (Table 1.)  One subject, #1, was diagnosed at an early age 
because of known family history of ET and likely has hereditary and not 
sporadic disease (see below.)  Initial symptoms for subject #6 included 
abdominal pain and splenomegaly.  Subject #8 initially presented with fatigue 
and unexplained itching.  Subject #5 presented with nose bleeding.  The 
remaining four subjects all had presentations that included headache as one 
of their main complaints. 
 
Family History 
 Because of the differences between hereditary and sporadic disease, a 
detailed family history was obtained from each subject.  As previously 
mentioned, Subject #1 has a positive family history for MPN (Figure 1.)  His 
father has a diagnosis of ET (JAK2V617F negative), made on routine testing, 
and his paternal great grandmother has a reported history of PV.  His mother 
(diagnosed after having a transient ischemic attack) and maternal aunt both 
have ET (mother is JAK2V617F negative as well.)  His maternal grandmother 
also has a diagnosis of ET, and his maternal great-grandfather had an MI at 
an early age and died of a stroke.  He has a healthy younger sister with 
normal blood counts.  There is no consanguinity between the parents. 
 All other subjects have negative family histories regarding possible 
MPN.  Questioning regarding diagnoses such as a known diagnosis of MPN, 
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significant thrombotic or bleeding events, or AML were asked.  The seven 
additional subjects appear to have sporadic disease. 
Figure 1. Family Tree for Subject #1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #1 is identified by * 
ITP= Idiopathic Thrombocytopenic Purpura, TIA=Transient Ischemic Attack, 
MI=Myocardial Infarction 
 
Common Clinical and Laboratory Features 
MPN are often associated with a variety of constitutional symptoms, 
such as erythromelalgia (a neurovascular syndrome leading to painful redness 
and inflammation, generally in the hands and feet), abdominal discomfort, 
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itching, and headache.  One subject experienced erythromelalgia during her 
illness, while two additional subjects experienced episodes of discoloration 
and paresthesias during the course of the illness.  All of the subjects have 
experienced periods of persistent headache during their illness (Table 2.)  One 
subject has had splenomegaly and abdominal discomfort during his illness, 
one subject experienced significant itching, and one subject has had difficulty 
sleeping.    
Extreme thrombocytosis is defined as a platelet count > 1,000,000 x 
109/L.  All of the subjects enrolled have had extreme thrombocytosis at one 
point during their illness.  Acquired von Willebrand’s disease can occur in the 
setting of extreme thrombocytosis, and three subjects developed this during 
the course of their illness. 
Table 2 – Clinical Findings in Pediatric Patients 
 
 
 
 
Subject 
# 
Symptoms 
Experienced 
Extreme 
Thrombocytosis Adverse Event 
1 
Weakness, Headache, 
Paresthesias Yes Laryngospasm 
2 Headache Yes --- 
3 
Headache, Fatigue, 
Paresthesias Yes --- 
4 
Erythromelalgia, 
Headache Yes --- 
5 Nose bleeding Yes --- 
6 
Abdominal Discomfort, 
Splenomegaly Yes --- 
7 Headache Yes 
Pseudotumor 
Cerebri 
8 Fatigue, Itching Yes --- 
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Serious Adverse Clinical Events 
 The most concerning outcomes associated with MPN include severe 
hemorrhage, thrombotic events, or conversion from another MPN to 
secondary myelofibrosis, or transformation to acute myeloid leukemia (AML.)  
None of the eight subjects had a severe thrombotic or hemorrhagic event, and 
none have transformed to AML.  
Subject #1 experienced three episodes of severe laryngospasm, 
associated with difficulty breathing, anxiety, and fecal incontinence.  
Neurological evaluation showed no evidence of seizure, stroke or vascular 
events.  He is doing well with dietary modification, speech therapy, 
psychotherapy, and monitoring by ENT.  Subject #7 had an episode of 
worsening headache and was ultimately found to have pseudotumor cerebri.  
CNS imaging revealed no evidence of stroke or vascular event and she is 
doing well symptomatically with medication. 
 
Therapeutic Management 
Limited data exists regarding suggested management for pediatric 
patients with MPN and there is some variation in recommendations regarding 
when to treat and what agents are first line.  Among these subjects, four of 
them received aspirin during the course of their illness, provided at 2 different 
medical centers (Table 3.)  Six of these subjects received hydroxyurea therapy 
at some point from six different treating institutions.  None of the subjects 
received alternative cytoreductive agents. 
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           Table 3 – Therapies Prescribed to Pediatric MPN Patients 
Subject # Aspirin Hydroxyurea Alternative Agent 
1 Yes -- No 
2 Yes -- No 
3 Yes Yes No 
4 Yes Yes No 
5 -- Yes No 
6 -- Yes No 
7 -- Yes No 
8 -- Yes No 
 
 
Clinical Genetic Evaluation 
 As part of their diagnostic work-up, genetic testing was performed on all 
subjects for JAK2V617F mutation.  Three subjects (#3, #9, and #10) are 
positive for the JAK2V617F mutation, giving a prevalence rate of 37.5%.  Of 
the JAK2V617F negative patients, all five were negative for mutations in MPL.  
An additional three patients have been tested for CALR mutations and were 
negative as well, placing them in the “triple negative” MPN category (Table 4.) 
 
 
 Table 4 – Clinical Genetic Testing of Pediatric MPN Subjects 
Subject # JAK2 MPL CALR 
1 (-) (-) (-) 
2 (-) (-) NT 
3 (+) NT NT 
4 (-) (-) (-) 
5 (-) (-) NT 
6 (-) (-) (-) 
7 (+) NT NT 
8 (+) NT NT 
NT = not tested 
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Genomic Analysis 
 DNA samples for an initial portion of the subjects were submitted for 
additional sequencing utilizing a gene panel containing close to 400 genes 
with potential relevance to MPN and hematologic malignancies (subjects 
#1,2,4, and 7.)  As was seen in commercial testing, patients tested were not 
found to have any JAK2, MPL, or CALR mutations. 
 Sequencing demonstrated mutations in various genes of interest in 
cancer and MPN.  Table 5 summarizes a group of mutations identified that 
may be of interest in this population, including TET2 and EZH2, previously 
identified in MPN.  Of great interest are JAK1V658F and NRASQ61K (Figure 
1), two mutations identified as pathogenic in other malignancies (ALL and 
Melanoma, respectively.)  These particular mutations have not been 
previously reported in MPN patients and mutations listed below were each 
only identified in 1 subject.  However, some of these were identified in AML 
patient samples that were sequenced on the same panel of genes. 
 
Table 5 – Mutations of Interest in Initial Sequencing Data 
Gene AA Alteration Tumor Var Frequency 
Normal Var 
Frequency 
JAK1 V658F 0.504 0 
NRAS Q61K 0.51 0 
EZH2 R207L 0.143 0 
JAK3 P151R 0.401 0 
TET2 Q1084P 0.345 0 
TP53 V274D 1 0 
CSF3R D320N 0.524 0 
STAT5B R294C 0.689 0 
ASXL1 E1023D 0.513 0 
IL7R I122V 0.532 0             
var = variant 
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Figure 2. Previously Identified Oncogenic Mutations Found in Pediatric 
MPN Patients 
 
 
NRASQ61K – Subject #2 
 
JAK1V658F – Subject #1 
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Assessment of Individual Mutations 
 Mutations of interest will be assessed for their potential to be 
pathogenic, as well as their ability to be inhibited with targeted therapeutics, 
with JAK1V658F being the first mutation evaluated.  Ba/F3 cells, a murine 
interleukin-3-dependent cell line, were successfully transduced with 
hJAK1V658F.  Expression of JAK1V658F allowed for cytokine independent 
growth in the transduced cells, and showed constitutive activation of 
JAK/STAT signaling.  Ruxolitinib is a JAK1/2 selective inhibitor that has been 
evaluated in patients with MPN and malignancies.  Treatment of the Ba/F3-
JAK1V658F cells with INCB18424, the laboratory-grade Ruxolitinib compound, 
showed dose-dependent inhibition of cell growth in the Ba/F3-JAK1V658F.  
While phosphorylation of JAK1 is not inhibited by treatment with specific JAK 
inhibition, loss of activation of downstream mediator STAT proteins is 
observed.  HSP90 inhibition has been shown to combat resistance to targeted 
therapeutics in JAK-mutated disease models, and PU-H71, a purine scaffold 
HSP90 inhibitor is in clinical trial for patients with MPN and leukemia.  
Treatment of the Ba/F3-JAK1V658F cells with PU-H71 also showed inhibition 
of cell growth and also inhibited activation of JAK/STAT signaling, including 
elimination of phosphorylated JAK1. 
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 Figure 3 – Transformation of Ba/F3 Cells With JAK1V658F 
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DISCUSSION 
 
Our results show the spectrum of disease in a small cohort of pediatric 
MPN patients.  It is clear MPN can occur in children of any age.  Hereditary 
disease is less common than sporadic disease.  Diagnosis in children with 
MPN almost always involved a bone marrow evaluation, which is important as 
the diagnostic criteria of the World Health Organization, the Polycythemia Vera 
Study Group, and the British Committee for Standards in Haematology all 
include bone marrow findings as part of their diagnostic criteria.  It was 
recommended to Subject #8 that she undergoes a bone marrow evaluation to 
ensure she had the proper MPN diagnosis. 
Children with MPN show similar symptoms as adults with MPN, such as 
headache, fatigue, and erythromelalgia. However, none of the subjects have 
yet experienced any traditional “high-risk” events, including thrombotic events, 
hemorrhagic events, or transformation to AML.  The laryngospasm episodes 
experienced by Subject #1 and the development of pseudotumor cerebri in 
subject #8 are not clearly linked to their underlying MPN diagnoses.   
Use of aspirin is standardly accepted in patients with PV and is often 
used in ET patients with microvascular symptoms.  Here, two centers utilized 
low-dose aspirin in four subjects.  The use of cytoreductive therapy is 
generally reserved for “high-risk” patients or those with significant symptoms 
refractory to aspirin therapy.  In our cohort, six different centers started 
pediatric subjects on hydroxyurea therapy with six of the eight being treated 
with hydroxyurea.  At the time of starting hydroxyurea, all children had extreme 
thrombocytosis and varied clinical symptoms but no serious clinical adverse 
events had occurred.   Practitioners treating children seem more comfortable 
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starting cytoreductive therapy in the setting of extreme thrombocytosis rather 
than not treating. 
Our cohort seemed consistent with published literature that rates of 
known MPN mutations in children are lower than in adults, with lower rates of 
JAK2, MPL, and CALR mutations.  Initial sequencing showed mutations in a 
variety of genes that have been associated with MPN and myeloid disease, as 
well as alternative genes that have been associated with other malignancies.  
The mutations listed above are in genes that can directly or indirectly interact 
with the JAK/STAT signaling pathway and common downstream mediators.  It 
is possible to assess these genes for their transformative potential and study 
various potential therapeutics using in vitro models.  This implies that 
alternative genes from those identified in adults may be involved in disease 
pathogenesis but they can ultimately act through similar and interacting 
downstream mediators. 
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     FUTURE DIRECTIONS 
 
This project served as a successful pilot to determine if pediatric MPN 
can be explored further.  It provided baseline clinical and genomic data on a 
small cohort of patients and showed the feasibility of genetic evaluations.  
Moving forward, there are important questions to answer and additional steps 
to be taken in order to develop a comprehensive pediatric MPN research 
program. 
The key, principal question to be explored in detail is what type of 
disease these children actually have.  Are pediatric MPN the same diseases 
as those that affect adults, or are they different?  Based on this, I would ask 
whether the same diagnostic and assessment tools apply to children?  
Additionally, can management of adults then be extrapolated to children?   
The first element of answering this line of questioning is expanding my 
clinical analysis to tease out hereditary from sporadic diseases.  While cohorts 
of children with both categories of disease will be important to study and will 
be included in the database, they may prove to show different phenotypes and 
genotypes over time.  Being able to distinguish between these classes of MPN 
may ultimately be determined by these differences but must initially begin with 
a thorough family history.  To ensure a uniform and detailed analysis of each 
future subject, I will develop a family history questionnaire that will not only 
capture those clearly diagnosed with an MPN but will also identify any 
potential relatives who have gone undiagnosed based on their histories of 
relevant symptoms, clinical findings, and additional diagnoses (such as 
unexplained splenomegaly, unexplained thrombosis or hemorrhage, and 
episodes of MDS or AML.)    
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To gain insight regarding hereditary versus familial ET, I will confirm an 
even more detailed family history of subject #1 and will pursue testing of as 
many of his family members as possible, include germline testing of any 
healthy relatives (including his sister and paternal aunt) in order to increase 
my chances of identifying the causative mutations in this family.  I will work 
with the family and the assistance of a statistician and genetic counselor to 
determine the family members who will need to be included in the evaluation 
and numbers needed to make significant assessments.  Whole exome 
sequencing and cytogenetic evaluation, rather than a more targeted panel, will 
be pursued in available family members, and will be analyzed in a similar 
fashion to the subjects who underwent gene-panel sequencing.  Tumor 
samples will be compared to germline to assess for loss of heterozygosity.  
Public mutational and SNP databases will be queried to identify potential new 
mutations. The maternal side of the family has a high penetrance of patients 
only with ET, while the paternal side has various MPN.  Both parents were 
negative for JAK2V617F and this family provides a potentially unique genetic 
situation that has a high potential for identifying a novel mutation and 
informing on the pathogenesis of inherited MPNs.  
The next step in answering these questions is to obtain more significant 
information on MPN in children.  There are clear criteria for defining MPN in 
adults, yet as we identify new causative lesions, experts call for revisions of 
diagnostic criteria25.  While bone marrow findings seem similar in pediatric 
and adult patients, the mutations that define disease are likely different, and 
laboratory values may also have different parameters for diagnosis.  By 
meticulously tracking the symptoms and laboratory findings present at 
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diagnosis and correlating them with bone marrow and genomic findings, we 
may identify alternative criteria that define true pediatric disease. 
Teasing out the symptoms that are specific to pediatric patients is 
crucial to allow this to happen.  Symptom assessment tools exist for adult 
patients with MPN, which are important for assessing symptomatic disease 
burden and treatment effectiveness26.  Utilizing pilot data obtained from this 
study, as well as published data on pediatric MPN, I will design a pediatric 
symptom assessment tool to administer to subjects.  It will likely require 
parental involvement and will incorporate certain pediatric-specific tools such 
as pain/discomfort assessment scales designed for use in children. 
An additional area that can be queried is cytokine profiling in children 
with MPN.  Cytokine up-regulation is a known element of MPN in adults, and is 
thought to contribute to symptom burden.  This area has not previously been 
explored in children diagnosed with MPN.  Therefore, I will evaluate cytokine 
expression (including IL-6, IL-10, and TNF-α) in both serum and through 
single-cell assays of harvested blood and, if available, bone marrow cells, 
utilizing techniques that have previously been described by members of our 
lab27. 
In addition to determining the similarities and differences in clinical 
findings between children and adults, additional disease elements will need to 
be assessed.  The genomic analysis will need further evaluation to identify 
potential driver mutations, as well as co-occurring mutations that may affect 
disease pathogenesis or progression.  Utilizing SNP and mutational databases 
and assessing transformative ability (as demonstrated above) will be important 
aspects of identifying those mutations that are of actual relevance.  If the gene 
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panel does not provide answers, whole exome sequencing will likely be the 
necessary next step. 
Evaluating transcriptional profiles will be an important tool to 
understand disease phenotypes in children and examine the influence of 
newly identified mutations.  I will explore transcriptional signatures in pediatric 
samples to determine if they show up-regulation of JAK/STAT target genes, as 
has previously been shown in our lab with adult MPN patients28.  I will also 
assess the effect of various mutations I identify on the transcriptional profiles 
in the in-vitro cell line models I develop to determine how these mutations 
affect wild-type gene expression to evaluate their potential to cause or alter 
disease.  This will also need to be done on the familial samples for subject 
#1’s family. 
Targeted therapy with Ruxolitinib, while not leading to significant 
decreases in allele burden, has shown significant symptomatic improvement in 
adults with MPN.  It is possible that it can have symptomatic benefits in 
children without the potential risks associated with Hydroxyurea treatment in 
these pre-malignant conditions.  The Children’s Oncology Group has 
conducted a small Phase I study with Ruxolitinib in children with various 
malignant and pre-malignant conditions and has shown that it can safely be 
given.  I will plan to set up talks with Novartis, the makers of Ruxolitinib, to 
develop a small Phase I trial of Ruxolitinib in children with MPN to determine if 
count improvement and symptom burden improve with a short course of 
treatment. 
To allow me to accomplish any of these goals, I will need to drastically 
increase my subject recruitment.  This will require a multi-faceted approach 
since these are rare diseases in children.  One key resource I have available 
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to me to reach my pediatric hematology/oncology colleagues is the numerous 
professional societies I have membership in.  I will work with leaders from the 
Children’s Oncology Group, the American Society of Hematology, and the 
American Society of Pediatric Hematology and Oncology, as well as my 
mentor Dr. Bussel, to present my research plan to fellow members who likely 
have MPN patients in their programs.  This will also allow me to identify any 
sample banks that may exist (such as within the Children’s Oncology Group) 
of pediatric MPN or post-MPN samples that I can use in my research. 
Direct contact with colleagues will be an important way to make a direct 
appeal for the importance of including as many pediatric MPN patients as 
possible in this research program.  Working with my mentor Dr. Bussel, I will 
develop a list of the major pediatric hematology/oncology programs in the 
country.  I will develop a letter explaining the research program, the goals, and 
what patients are needed.  I will also identify key groups from which to request 
collaborators to help tackle some of the questions we want answered and to 
help grow the research program, which will be mutually beneficial.  I will also 
identify the appropriate person from each of the large New York programs for 
me to make a personal appeal to in order to rapidly start acquiring patients 
and disseminating information about our program.  Using the contacts of both 
Drs. Bussel and Levine and our knowledge of other major MPN research 
programs, I will reach out to any potential collaborators in major academic 
centers in the US, as well as in Europe and Asia, to identify any sample banks 
of patients who were diagnosed with MPNs before the age of 21 years old but 
may be seen by adult practitioners.  It is likely that there are a number of 
patients with MPNs who were diagnosed earlier in life but due to lack of 
available experts are followed by adult providers.  
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Another key area for recruitment will be to appeal to patients 
themselves.  I will do this in a number of different ways.  First, I will meet with 
the leadership of my department and the NYP/WCMC public relations group to 
help develop a web page for our pediatric MPN program. Social media is a 
very successful tool to recruit patients for clinical research, and I will make 
sure that we have a website explaining our goals and plans and providing the 
appropriate information for interested patients and families to reach us.  I will 
also work with patient organizations, such as the MPN Research Foundation.  
I have begun speaking to the head of this organization, which is a wealth of 
resources for patients and researchers.  Utilizing their membership and social 
media sites and meetings, I will plan to disseminate information to patients and 
providers regarding the opportunities for research.  Lastly, I will appeal directly 
to the families of my patients.  A number of them have expressed interest in 
the research program and often have contact with other families whose 
children have MPN.  With their help I will be able to spread the word to 
additional families in various parts of the country.  Utilizing all these outlets will 
hopefully allow me to gather a significant number of samples to answer the 
questions laid out above and develop my expertise in this neglected area of 
pediatric hematology/oncology. 
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  CONCLUSIONS 
 
 Children with MPN have similar common clinical symptoms to adults, 
yet have less frequent episodes of serious adverse events.  Pediatric 
hematologists frequently utilize hydroxyurea in the management of MPN in 
children in the absence of adverse clinical events.  These children have lower 
rates than adults of known pathogenic mutations, but may have driver 
mutations in genes that interact with similar pathways.  Further evaluation of 
both phenotypic and genotypic outcomes in this population is needed to allow 
for true characterization of the nature of these diseases in children, and to 
ultimately allow for the development of comprehensive pediatric MPN 
programs and accepted management guidelines. 
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